BRD4: An emerging prospective therapeutic target in glioma
Despite advances in treatment, the prognosis for glioma patients remains poor. Bromodomain-containing protein 4 (BRD4), a member of the bromodomain and extraterminal (BET) protein family, plays an important role in controlling oncogene expression and genome stability. In recent years, numerous BRD4...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-06-01
|
Series: | Molecular Therapy: Oncolytics |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2372770521000371 |
id |
doaj-300fb4c22d8040d388e408f08050f6d3 |
---|---|
record_format |
Article |
spelling |
doaj-300fb4c22d8040d388e408f08050f6d32021-06-27T04:38:46ZengElsevierMolecular Therapy: Oncolytics2372-77052021-06-0121114BRD4: An emerging prospective therapeutic target in gliomaHua Yang0Li Wei1Yang Xun2Anping Yang3Hua You4Department of Basic Medicine and Biomedical Engineering, School of Medicine, Foshan University, Foshan 528000, Guangdong Province, ChinaAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, Guangdong Province, ChinaDepartment of Basic Medicine and Biomedical Engineering, School of Medicine, Foshan University, Foshan 528000, Guangdong Province, ChinaDepartment of Basic Medicine and Biomedical Engineering, School of Medicine, Foshan University, Foshan 528000, Guangdong Province, ChinaAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, Guangdong Province, China; Corresponding author: Hua You, MD, PhD, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, No. 78 Heng-Zhi-Gang Road, Yue Xiu District, Guangzhou 510095, Guangdong Province, China.Despite advances in treatment, the prognosis for glioma patients remains poor. Bromodomain-containing protein 4 (BRD4), a member of the bromodomain and extraterminal (BET) protein family, plays an important role in controlling oncogene expression and genome stability. In recent years, numerous BRD4 inhibitors have entered clinical trials and achieved exciting results in tumor treatment. Recent clinical studies have shown that BRD4 expression in glioma is significantly higher than in the adjacent normal brain tissue. BRD4 inhibitors effectively penetrate the blood-brain barrier and target glioma tumor tissues but have little effect on normal brain tissues. Thus, BRD4 is a target for the treatment of glioma. In this study, we discuss the progress in the use of BRD4 inhibitors for glioma treatment, their mechanism of action, and their broad potential clinical application.http://www.sciencedirect.com/science/article/pii/S2372770521000371gliomabromodomain and extraterminal protein familyBRD4small molecular inhibitors |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hua Yang Li Wei Yang Xun Anping Yang Hua You |
spellingShingle |
Hua Yang Li Wei Yang Xun Anping Yang Hua You BRD4: An emerging prospective therapeutic target in glioma Molecular Therapy: Oncolytics glioma bromodomain and extraterminal protein family BRD4 small molecular inhibitors |
author_facet |
Hua Yang Li Wei Yang Xun Anping Yang Hua You |
author_sort |
Hua Yang |
title |
BRD4: An emerging prospective therapeutic target in glioma |
title_short |
BRD4: An emerging prospective therapeutic target in glioma |
title_full |
BRD4: An emerging prospective therapeutic target in glioma |
title_fullStr |
BRD4: An emerging prospective therapeutic target in glioma |
title_full_unstemmed |
BRD4: An emerging prospective therapeutic target in glioma |
title_sort |
brd4: an emerging prospective therapeutic target in glioma |
publisher |
Elsevier |
series |
Molecular Therapy: Oncolytics |
issn |
2372-7705 |
publishDate |
2021-06-01 |
description |
Despite advances in treatment, the prognosis for glioma patients remains poor. Bromodomain-containing protein 4 (BRD4), a member of the bromodomain and extraterminal (BET) protein family, plays an important role in controlling oncogene expression and genome stability. In recent years, numerous BRD4 inhibitors have entered clinical trials and achieved exciting results in tumor treatment. Recent clinical studies have shown that BRD4 expression in glioma is significantly higher than in the adjacent normal brain tissue. BRD4 inhibitors effectively penetrate the blood-brain barrier and target glioma tumor tissues but have little effect on normal brain tissues. Thus, BRD4 is a target for the treatment of glioma. In this study, we discuss the progress in the use of BRD4 inhibitors for glioma treatment, their mechanism of action, and their broad potential clinical application. |
topic |
glioma bromodomain and extraterminal protein family BRD4 small molecular inhibitors |
url |
http://www.sciencedirect.com/science/article/pii/S2372770521000371 |
work_keys_str_mv |
AT huayang brd4anemergingprospectivetherapeutictargetinglioma AT liwei brd4anemergingprospectivetherapeutictargetinglioma AT yangxun brd4anemergingprospectivetherapeutictargetinglioma AT anpingyang brd4anemergingprospectivetherapeutictargetinglioma AT huayou brd4anemergingprospectivetherapeutictargetinglioma |
_version_ |
1721358491460829184 |